Amicus Therapeutics, Inc. (FOLD) Revenue History
Annual and quarterly revenue from 2005 to present
FOLD Revenue Over Time (2005–2025)
FOLD Revenue Growth History
13 of 17 years with positive growth- FY2005 revenue growth
- N/A
- FY2006 revenue growth
- N/A
- FY2007 revenue growth
- N/A
- FY2008 revenue growth
- +739.0%
- FY2009 revenue growth
- +330.0%
- FY2010 revenue growth
- -98.6%
- FY2011 revenue growth
- +2224.7%
- FY2012 revenue growth
- -14.1%
- FY2013 revenue growth
- -98.0%
- FY2014 revenue growth
- +237.2%
- FY2015 revenue growth
- -100.0%
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- +644.9%
- FY2018 revenue growth
- +147.1%
- FY2019 revenue growth
- +99.7%
- FY2020 revenue growth
- +43.2%
- FY2021 revenue growth
- +17.1%
- FY2022 revenue growth
- +7.8%
- FY2023 revenue growth
- +21.3%
- FY2024 revenue growth
- +32.3%
- FY2025 revenue growth
- +20.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $185.2M | +23.7% |
| Q3 2025 | $169.1M | +19.5% |
| Q2 2025 | $154.7M | +22.1% |
| Q1 2025 | $125.2M | +13.4% |
| Q4 2024 | $149.7M | +30.1% |
| Q3 2024 | $141.5M | +36.7% |
| Q2 2024 | $126.7M | +34.0% |
| Q1 2024 | $110.4M | +28.0% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown
FOLD's revenue distribution by segment and geography
By Geography
FOLD Revenue Analysis (2005–2025)
Current Revenue & Growth
As of June 21, 2026, Amicus Therapeutics, Inc. (FOLD) generated trailing twelve-month (TTM) revenue of $634.2 million, reflecting exceptional growth of +23.7% year-over-year. The most recent quarter (Q4 2025) recorded $185.2 million in revenue, up 9.6% sequentially.
Historical Growth Trajectory
FOLD's 5-year compound annual growth rate (CAGR) stands at +19.4%, indicating consistent double-digit revenue growth. The 3-year CAGR of +24.4% exceeds the 5-year average, indicating an acceleration in the most recent period. Amicus Therapeutics, Inc.'s highest annual revenue of $634.2 million was recorded in 2025, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including RARE (+13.3% YoY), SRPT (-2.2% YoY), and BMRN (+9.9% YoY) — FOLD has outperformed the peer group in revenue growth. Compare FOLD vs RARE →
FOLD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FOLDCurrent | $634M | +23.7% | +19.4% | 5.4% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 BMRN | $3.2B | +9.9% | +11.6% | 16.6% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 KRYS | $389M | +25.1% | - | 41.5% |
FOLD Historical Revenue Data (2005–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $634.2M | +20.0% | $553.8M | 87.3% | $34.5M | 5.4% |
| 2024 | $528.3M | +32.3% | $475.4M | 90.0% | $24.9M | 4.7% |
| 2023 | $399.4M | +21.3% | $362.0M | 90.7% | $-77,211,000 | -19.3% |
| 2022 | $329.2M | +7.8% | $290.6M | 88.3% | $-212,120,000 | -64.4% |
| 2021 | $305.5M | +17.1% | $271.0M | 88.7% | $-206,434,000 | -67.6% |
| 2020 | $260.9M | +43.2% | $229.8M | 88.1% | $-246,998,000 | -94.7% |
| 2019 | $182.2M | +99.7% | $160.3M | 87.9% | $-304,037,000 | -166.8% |
| 2018 | $91.2M | +147.1% | $76.8M | 84.2% | $-328,777,000 | -360.3% |
| 2017 | $36.9M | +644.9% | $30.7M | 83.1% | $-441,985,000 | -1196.8% |
| 2016 | $5.0M | - | $4.1M | 83.2% | $-181,890,000 | -3668.6% |
| 2015 | $0 | -100.0% | $-1,833,000 | - | $-130,437,000 | - |
| 2014 | $1.2M | +237.2% | $1.2M | 100.0% | $-68,701,000 | -5612.8% |
| 2013 | $363K | -98.0% | $-13,129,000 | -3616.8% | $-64,181,000 | -17680.7% |
| 2012 | $18.4M | -14.1% | $-1,966,000 | -10.7% | $-52,931,000 | -287.5% |
| 2011 | $21.4M | +2224.7% | $21.4M | 100.0% | $-50,887,000 | -237.4% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
21+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
FOLD — Frequently Asked Questions
Quick answers to the most common questions about buying FOLD stock.
Is FOLD's revenue growth accelerating or slowing?
FOLD revenue growth is accelerating. TTM revenue reached $634M, up +23.7% year-over-year — ahead of the 5-year CAGR of +19.4%. This indicates the business is expanding faster than its historical baseline.
What is FOLD's revenue history from 2005 to 2026?
Amicus Therapeutics, Inc. (FOLD) revenue history spans 2005 to 2026. TTM revenue as of 2026 is $634M, growing at +23.7% YoY. The 5-year CAGR is +19.4%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is FOLD's long-term revenue growth rate (CAGR)?
Amicus Therapeutics, Inc.'s 5-year revenue CAGR of +19.4% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +23.7% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for FOLD.
Why does FOLD's quarterly revenue fluctuate?
FOLD quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Amicus Therapeutics, Inc.'s revenue data from 2005 to 2026 shows full historical quarterly detail on this page.
How is FOLD's revenue distributed by segment?
FOLD reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does FOLD's revenue compare to industry peers?
Amicus Therapeutics, Inc. (FOLD) with TTM revenue of $634M and +23.7% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.